Skip to main content
Erschienen in: Obesity Surgery 11/2016

03.05.2016 | Original Contributions

Short- and Long-Term Effects of Weight Loss on the Complement Component C3 After Laparoscopic Gastric Bypass in Obese Patients

verfasst von: Segundo Á. Gómez-Abril, Carlos Morillas-Ariño, Jose L. Ponce-Marco, Teresa Torres-Sánchez, Fernando Delgado-Gomis, Antonio Hernández-Mijares, Milagros Rocha

Erschienen in: Obesity Surgery | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

The C3 complement component (C3c) is increasingly recognized as a cardiometabolic risk factor, but how it is affected after weight loss through gastric bypass is a question yet to be answered.

Methods

A total of 66 obese patients underwent laparoscopic gastric bypass. Anthropometric parameters, total cholesterol (TC), triglycerides, high-density lipoprotein cholesterol (HDLc), low-density lipoprotein cholesterol (LDLc), glucose, insulin, HOMA-IR, liver enzymes, high-sensitivity C-reactive protein (hsCRP), and C3c levels were evaluated at baseline and at 1 and 5 years post-surgery.

Results

All anthropometric and biochemical parameters improved significantly after surgery, although a deterioration was detected with respect to the percentage of excess of weight loss, insulin, TC, LDLc, and lactate dehydrogenase 5 years post-surgery. Despite this, a remission rate of 84 % was observed in the presence of metabolic syndrome after 5 years follow-up. hsCRP and C3c were reduced significantly after surgery and maintained throughout the experimental period. In addition, C3c was correlated with BMI and insulin at all time points. The multivariate regression model, in which C3c was a dependent variable, revealed that aspartate aminotransferase and BMI were independent variables at baseline, alkaline phosphatase and insulin were independent at 1 year post-surgery, and insulin, BMI, and TC were independent at 5 years post-surgery.

Conclusions

C3c may be a marker of the chronic inflammatory process underlying insulin resistance. Its association with BMI and liver enzymes supports a major role in metabolic activity, although future research is needed to clarify the nature of the molecular mechanisms involved and the physiological significance of these findings.
Literatur
1.
2.
Zurück zum Zitat Haskard DO, Boyle JJ, Mason JC. The role of complement in atherosclerosis. Curr Opin Lipidol. 2008;19:478–82.CrossRefPubMed Haskard DO, Boyle JJ, Mason JC. The role of complement in atherosclerosis. Curr Opin Lipidol. 2008;19:478–82.CrossRefPubMed
3.
Zurück zum Zitat Onat A, Can G, Rezvani R, et al. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta. 2011;412:1171–9.CrossRefPubMed Onat A, Can G, Rezvani R, et al. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta. 2011;412:1171–9.CrossRefPubMed
4.
5.
Zurück zum Zitat Wlazlo N, van Greevenbroek MM, Ferreira I, et al. Complement factor 3 is associated with insulin resistance and with incident type 2 diabetes over a 7-year follow-up period: the CODAM Study. Diabetes Care. 2014;37:1900–9.CrossRefPubMed Wlazlo N, van Greevenbroek MM, Ferreira I, et al. Complement factor 3 is associated with insulin resistance and with incident type 2 diabetes over a 7-year follow-up period: the CODAM Study. Diabetes Care. 2014;37:1900–9.CrossRefPubMed
7.
Zurück zum Zitat Gabrielsson BG, Johansson JM, Lönn M, et al. High expression of complement components in omental adipose tissue in obese men. Obes Res. 2003;11:699–708.CrossRefPubMed Gabrielsson BG, Johansson JM, Lönn M, et al. High expression of complement components in omental adipose tissue in obese men. Obes Res. 2003;11:699–708.CrossRefPubMed
8.
Zurück zum Zitat Hernández-Mijares A, Jarabo-Bueno MM, López-Ruiz A, et al. Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors. Int J Obes. 2007;31:927–32.CrossRef Hernández-Mijares A, Jarabo-Bueno MM, López-Ruiz A, et al. Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors. Int J Obes. 2007;31:927–32.CrossRef
9.
Zurück zum Zitat Peake PW, Kriketos AD, Campbell LV, et al. Response of the alternative complement pathway to an oral fat load in first-degree relatives of subjects with type II diabetes. Int J Obes. 2005;29:429–35.CrossRef Peake PW, Kriketos AD, Campbell LV, et al. Response of the alternative complement pathway to an oral fat load in first-degree relatives of subjects with type II diabetes. Int J Obes. 2005;29:429–35.CrossRef
10.
Zurück zum Zitat Hanusch-Enserer U, Cauza E, Spak M, et al. Acute-phase response and immunological markers in morbid obese patients and patients following adjustable gastric banding. Int J Obes Relat Metab Disord. 2003;27:355–61.CrossRefPubMed Hanusch-Enserer U, Cauza E, Spak M, et al. Acute-phase response and immunological markers in morbid obese patients and patients following adjustable gastric banding. Int J Obes Relat Metab Disord. 2003;27:355–61.CrossRefPubMed
11.
Zurück zum Zitat Sakçak I, Avşar MF, Hamamci EO, et al. Comparison of early and late changes in immunoglobulins and acute phase reactants after laparoscopic adjustable gastric banding in patients with morbid obesity. Obes Surg. 2010;20:610–5.CrossRefPubMed Sakçak I, Avşar MF, Hamamci EO, et al. Comparison of early and late changes in immunoglobulins and acute phase reactants after laparoscopic adjustable gastric banding in patients with morbid obesity. Obes Surg. 2010;20:610–5.CrossRefPubMed
12.
Zurück zum Zitat Nestvold TK, Nielsen EW, Ludviksen JK, et al. Lifestyle changes followed by bariatric surgery lower inflammatory markers and the cardiovascular risk factors C3 and C4. Metab Syndr Relat Disord. 2015;13:29–35.CrossRefPubMed Nestvold TK, Nielsen EW, Ludviksen JK, et al. Lifestyle changes followed by bariatric surgery lower inflammatory markers and the cardiovascular risk factors C3 and C4. Metab Syndr Relat Disord. 2015;13:29–35.CrossRefPubMed
13.
Zurück zum Zitat Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–52.CrossRefPubMed Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–52.CrossRefPubMed
14.
Zurück zum Zitat Luján JA, Hernández Q, Frutos MD, et al. Laparoscopic gastric bypass in the treatment of morbid obesity. Preliminary results of a new technique. Surg Endosc. 2002;16:1658–62.CrossRefPubMed Luján JA, Hernández Q, Frutos MD, et al. Laparoscopic gastric bypass in the treatment of morbid obesity. Preliminary results of a new technique. Surg Endosc. 2002;16:1658–62.CrossRefPubMed
15.
16.
Zurück zum Zitat Magro DO, Geloneze B, Delfini R, et al. Long-term weight regain after gastric bypass: a 5-year prospective study. Obes Surg. 2008;18:648–51.CrossRefPubMed Magro DO, Geloneze B, Delfini R, et al. Long-term weight regain after gastric bypass: a 5-year prospective study. Obes Surg. 2008;18:648–51.CrossRefPubMed
17.
Zurück zum Zitat Meguid MM, Glade MJ, Middleton FA. Weight regain after Roux-en-Y: a significant 20% complication related to PYY. Nutrition. 2008;24:832–42.CrossRefPubMed Meguid MM, Glade MJ, Middleton FA. Weight regain after Roux-en-Y: a significant 20% complication related to PYY. Nutrition. 2008;24:832–42.CrossRefPubMed
18.
Zurück zum Zitat Faria SL, Kelly E, Faria OP. Energy expenditure and weight regain in patients submitted to Roux-en-Y gastric bypass. Obes Surg. 2009;19:856–9.CrossRefPubMed Faria SL, Kelly E, Faria OP. Energy expenditure and weight regain in patients submitted to Roux-en-Y gastric bypass. Obes Surg. 2009;19:856–9.CrossRefPubMed
19.
Zurück zum Zitat Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.CrossRefPubMed Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.CrossRefPubMed
20.
Zurück zum Zitat Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.CrossRefPubMed Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.CrossRefPubMed
21.
Zurück zum Zitat Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B–12B. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B–12B.
22.
Zurück zum Zitat Després JP, Lemieux I, Dagenais GR, et al. HDL-cholesterol as a marker of coronary heart disease risk: the Québec Cardiovascular Study. Atherosclerosis. 2000;153:263–72.CrossRefPubMed Després JP, Lemieux I, Dagenais GR, et al. HDL-cholesterol as a marker of coronary heart disease risk: the Québec Cardiovascular Study. Atherosclerosis. 2000;153:263–72.CrossRefPubMed
23.
Zurück zum Zitat Ashen MD, Blumenthal RS. Clinical practice. Low HDL cholesterol levels. N Engl J Med. 2005;353:1252–60.CrossRefPubMed Ashen MD, Blumenthal RS. Clinical practice. Low HDL cholesterol levels. N Engl J Med. 2005;353:1252–60.CrossRefPubMed
24.
Zurück zum Zitat Rashid S, Barrett PH, Uffelman KD, et al. Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler Thromb Vasc Biol. 2002;22:483–7.CrossRefPubMed Rashid S, Barrett PH, Uffelman KD, et al. Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler Thromb Vasc Biol. 2002;22:483–7.CrossRefPubMed
25.
Zurück zum Zitat Côté M, Mauriège P, Bergeron J, et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab. 2005;90:1434–9.CrossRefPubMed Côté M, Mauriège P, Bergeron J, et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab. 2005;90:1434–9.CrossRefPubMed
26.
Zurück zum Zitat Broedl UC, Jin W, Rader DJ. Endothelial lipase: a modulator of lipoprotein metabolism upregulated by inflammation. Trends Cardiosvasc Med. 2004;14:202–6.CrossRef Broedl UC, Jin W, Rader DJ. Endothelial lipase: a modulator of lipoprotein metabolism upregulated by inflammation. Trends Cardiosvasc Med. 2004;14:202–6.CrossRef
27.
Zurück zum Zitat Nilsson B, Hamad OA, Ahlström H, et al. C3 and C4 are strongly related to adipose tissue variables and cardiovascular risk factors. Eur J Clin Invest. 2014;44:587–96.CrossRefPubMed Nilsson B, Hamad OA, Ahlström H, et al. C3 and C4 are strongly related to adipose tissue variables and cardiovascular risk factors. Eur J Clin Invest. 2014;44:587–96.CrossRefPubMed
28.
Zurück zum Zitat Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–5.CrossRefPubMed Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–5.CrossRefPubMed
29.
Zurück zum Zitat Hernández-Mijares A, Bañuls C, Bellod L, et al. Effect of weight loss on C3 and C4 components of complement in obese patients. Eur J Clin Invest. 2012;42:503–9.CrossRefPubMed Hernández-Mijares A, Bañuls C, Bellod L, et al. Effect of weight loss on C3 and C4 components of complement in obese patients. Eur J Clin Invest. 2012;42:503–9.CrossRefPubMed
30.
Zurück zum Zitat Anty R, Bekri S, Luciani N, et al. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, type 2 diabetes, and NASH. Am J Gastroenterol. 2006;101:1824–33.CrossRefPubMed Anty R, Bekri S, Luciani N, et al. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, type 2 diabetes, and NASH. Am J Gastroenterol. 2006;101:1824–33.CrossRefPubMed
31.
Zurück zum Zitat Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care. 1999;22:1971–7.CrossRefPubMed Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care. 1999;22:1971–7.CrossRefPubMed
32.
Zurück zum Zitat Vázquez LA, Pazos F, Berrazueta JR, et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab. 2005;90:316–22.CrossRefPubMed Vázquez LA, Pazos F, Berrazueta JR, et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab. 2005;90:316–22.CrossRefPubMed
33.
Zurück zum Zitat Anty R, Dahman M, Iannelli A, et al. Bariatric surgery can correct iron depletion in morbidly obese women: a link with chronic inflammation. Obes Surg. 2008;18:709–14.CrossRefPubMed Anty R, Dahman M, Iannelli A, et al. Bariatric surgery can correct iron depletion in morbidly obese women: a link with chronic inflammation. Obes Surg. 2008;18:709–14.CrossRefPubMed
34.
Zurück zum Zitat Vilarrasa N, Vendrell J, Sánchez-Santos R, et al. Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-alpha receptors, C-reactive protein and adiponectin in morbidly obese patients. Clin Endocrinol (Oxf). 2007;67:679–86.CrossRef Vilarrasa N, Vendrell J, Sánchez-Santos R, et al. Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-alpha receptors, C-reactive protein and adiponectin in morbidly obese patients. Clin Endocrinol (Oxf). 2007;67:679–86.CrossRef
35.
Zurück zum Zitat Rezvani R, Smith J, Lapointe M, et al. Complement receptors C5aR and C5L2 are associated with metabolic profile, sex hormones, and liver enzymes in obese women pre- and postbariatric surgery. J Obes. 2014;2014:383102.CrossRefPubMedPubMedCentral Rezvani R, Smith J, Lapointe M, et al. Complement receptors C5aR and C5L2 are associated with metabolic profile, sex hormones, and liver enzymes in obese women pre- and postbariatric surgery. J Obes. 2014;2014:383102.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat van Greevenbroek MM, Jacobs M, van der Kallen CJ, et al. The cross-sectional association between insulin resistance and circulating complement C3 is partly explained by plasma alanine aminotransferase, independent of central obesity and general inflammation (the CODAM Study). Eur J Clin Invest. 2011;41:372–9.CrossRefPubMed van Greevenbroek MM, Jacobs M, van der Kallen CJ, et al. The cross-sectional association between insulin resistance and circulating complement C3 is partly explained by plasma alanine aminotransferase, independent of central obesity and general inflammation (the CODAM Study). Eur J Clin Invest. 2011;41:372–9.CrossRefPubMed
37.
Zurück zum Zitat Muscari A, Antonelli S, Bianchi G, et al. Serum C3 is a stronger inflammatory marker of insulin resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate: comparison study in an elderly population. Diabetes Care. 2007;30:2362–8.CrossRefPubMed Muscari A, Antonelli S, Bianchi G, et al. Serum C3 is a stronger inflammatory marker of insulin resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate: comparison study in an elderly population. Diabetes Care. 2007;30:2362–8.CrossRefPubMed
38.
Zurück zum Zitat Yesilova Z, Ozata M, Oktenli C, et al. Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance. Am J Gastroenterol. 2005;100:842–9.CrossRefPubMed Yesilova Z, Ozata M, Oktenli C, et al. Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance. Am J Gastroenterol. 2005;100:842–9.CrossRefPubMed
39.
Zurück zum Zitat Fiorentino TV, Hribal ML, Andreozzi F, et al. Plasma complement C3 levels are associated with insulin secretion independently of adiposity measures in non-diabetic individuals. Nutr Metab Cardiovasc Dis. 2015;25:510–7.CrossRefPubMed Fiorentino TV, Hribal ML, Andreozzi F, et al. Plasma complement C3 levels are associated with insulin secretion independently of adiposity measures in non-diabetic individuals. Nutr Metab Cardiovasc Dis. 2015;25:510–7.CrossRefPubMed
40.
Zurück zum Zitat Barbu A, Hamad OA, Lind L, et al. The role of complement factor C3 in lipid metabolism. Mol Immunol. 2015;67:101–7.CrossRefPubMed Barbu A, Hamad OA, Lind L, et al. The role of complement factor C3 in lipid metabolism. Mol Immunol. 2015;67:101–7.CrossRefPubMed
41.
Zurück zum Zitat Maslowska M, Wang HW, Cianflone K. Novel roles for acylation stimulating protein/C3adesArg: a review of recent in vitro and in vivo evidence. Vitam Horm. 2005;70:309–32.CrossRefPubMed Maslowska M, Wang HW, Cianflone K. Novel roles for acylation stimulating protein/C3adesArg: a review of recent in vitro and in vivo evidence. Vitam Horm. 2005;70:309–32.CrossRefPubMed
42.
Zurück zum Zitat van Greevenbroek MM, Jacobs M, van der Kallen CJ, et al. Human plasma complement C3 is independently associated with coronary heart disease, but only in heavy smokers (the CODAM Study). Int J Cardiol. 2012;154:158–62.CrossRefPubMed van Greevenbroek MM, Jacobs M, van der Kallen CJ, et al. Human plasma complement C3 is independently associated with coronary heart disease, but only in heavy smokers (the CODAM Study). Int J Cardiol. 2012;154:158–62.CrossRefPubMed
43.
Zurück zum Zitat Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117:746–56.CrossRefPubMedPubMedCentral Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117:746–56.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Distelmaier K, Adlbrecht C, Jakowitsch J, et al. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost. 2009;102:564–72.PubMed Distelmaier K, Adlbrecht C, Jakowitsch J, et al. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost. 2009;102:564–72.PubMed
Metadaten
Titel
Short- and Long-Term Effects of Weight Loss on the Complement Component C3 After Laparoscopic Gastric Bypass in Obese Patients
verfasst von
Segundo Á. Gómez-Abril
Carlos Morillas-Ariño
Jose L. Ponce-Marco
Teresa Torres-Sánchez
Fernando Delgado-Gomis
Antonio Hernández-Mijares
Milagros Rocha
Publikationsdatum
03.05.2016
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 11/2016
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-016-2195-z

Weitere Artikel der Ausgabe 11/2016

Obesity Surgery 11/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.